Medical devices, healthcare technology and the business of care
PMA approval · P230036

Esprit BTK Everolimus Eluting Resorbable Scaffold System

ABBOTT MEDICAL · Decision date Apr 26, 2024

MEDTECHLEDGER EXPLANATIONP230036

What did the FDA approve?

The FDA approved the Esprit BTK Everolimus Eluting Resorbable Scaffold System from Abbott Medical on April 26, 2024. The approval covers improving luminal diameter in infrapopliteal lesions for patients with Chronic Limb Threatening Ischemia, where total scaffolding length reaches up to 170 mm and reference vessel diameter is between 2.5 mm and 4.00 mm.

The device is classified as an absorbable infrapopliteal scaffold under product code NXW in the cardiovascular specialty. The approval statement describes the indicated use but does not provide independent evidence of safety or clinical effectiveness. No supplement type or reason is listed, so the record does not indicate whether this is an original PMA or a change to a prior approval.

FDA approval order statement

The Esprit BTK Everolimus Eluting Resorbable Scaffold System is indicated for improving luminal diameter in infrapopliteal lesions in patients with Chronic Limb Threatening Ischemia (CLTI) and total scaffolding length up to 170 mm with a reference vessel diameter of >= 2.5 mm and <= 4.00 mm.
Regulatory pathway
Original PMA
Clinical specialty
Cardiovascular
Decision date
Apr 26, 2024

FDA source record · MedtechLedger’s explanation describes the recorded change.

Regulatory record facts

Identifier
P230036
Regulatory pathway
Premarket approval application
Product code
NXW
Decision code
APPR
Decision date
Apr 26, 2024
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: Scaffold, infrapopliteal, absorbable.

Product code
NXW
FDA device class
3

The approval statement above describes the scope recorded for this original decision. Later supplements may change the device or its indications.

FDA decision timeline

  1. P230036 received

    Application receipt date recorded by FDA.

  2. P230036 · FDA decision

    APPR

  3. P230036/S020 · Related supplement

    Esprit BTK Everolimus Eluting Resorbable Scaffold System

Timeline entries are records held by MedtechLedger for P230036. View FDA’s full supplement list.

Related devices and submissions

Same PMA: P230036

Product / regulatory recordCompanyPathwayDecision dateSource
ABBOTT MEDICALPMA supplementSep 24, 2026FDA

Explore the linked device profile

Regulatory context

An original PMA is a premarket approval application. The recorded approval scope is described in FDA’s order and supporting documents.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

Abbott Medical

Headquarters
Not reported
Brand website
abbott.com
FDA applicant address
3200 Lakeside Dr., Santa Clara, CA, 95054

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records